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Abstract
The strongest mucosal immune responses are induced following mucosal Ag delivery and
processing in the mucosal lymphoid tissues, and much is known regarding the immunological
parameters which regulate immune induction via this pathway. Recently, experimental systems
have been identified in which mucosal immune responses are induced following nonmucosal Ag
delivery. One such system, footpad delivery of Venezuelan equine encephalitis virus replicon
particles (VRP), led to the local production of IgA Abs directed against both expressed and
codelivered Ags at multiple mucosal surfaces in mice. In contrast to the mucosal delivery
pathway, little is known regarding the lymphoid structures and immunological components that
are responsible for mucosal immune induction following nonmucosal delivery. In this study, we
have used footpad delivery of VRP to probe the constituents of this alternative pathway for
mucosal immune induction. Following nonmucosal VRP delivery, J chain-containing, polymeric
IgA Abs were detected in the peripheral draining lymph node (DLN), at a time before IgA
detection at mucosal surfaces. Further analysis of the VRP DLN revealed up-regulated α4β7
integrin expression on DLN B cells, expression of mucosal addressin cell adhesion molecule 1 on
the DLN high endothelia venules, and production of IL-6 and CC chemokines, all characteristics
of mucosal lymphoid tissues. Taken together, these results implicate the peripheral DLN as an
integral component of an alternative pathway for mucosal immune induction. A further
understanding of the critical immunological and viral components of this pathway may
significantly improve both our knowledge of viral-induced immunity and the efficacy of viral-
based vaccines.
Because the vast majority of harmful pathogens rely on penetration of a mucosal barrier to
initiate infection, innate and adaptive immune mechanisms which uphold the integrity of the
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mucosal surface are paramount for mediating protection from invading microbes. To date,
vaccination has proven to be one of the most effective strategies of prophylactic immuno-
modulation against mucosal pathogens; however, mucosal infections with numerous viral,
bacterial, and fungal agents still pose a significant threat to human health. Therefore, the
development of vaccine regimens capable of stimulating protective mucosal immunity
represent a powerful opportunity to intercede in the disease course of many infectious
organisms (1).
It is well established that, compared with nonmucosal delivery, the strongest mucosal
immune responses are induced following mucosal Ag delivery (1–3). Stimulation of this
“natural pathway” occurs following nasal or oral Ag exposure and results in Ag capture and
processing in the MALT, found in close proximity to each mucosal surface (2, 4). As a
consequence, B cells enter the systemic circulation, up-regulate homing receptors, such as
the α4β7 integrin, and migrate back to the mucosal surface where they were activated (5, 6).
The α4β7 integrin (also termed the mucosal homing receptor) is critical for lymphocyte
homing to the small intestine where it binds to mucosal addressin cell adhesion molecule 1
(MAdCAM-1)5 on mucosal lymph node high endothelial venules (HEVs) (7, 8). Mucosal B
cells next differentiate into IgA-secreting plasma cells where they produce large amounts of
dimeric/polymeric IgA Abs by inclusion of the joining chain, or J chain, during Ab secretion
(9, 10). Indeed, J chain-containing IgA molecules are specifically transported onto mucosal
surfaces via the pIgR (11).
Although mucosal Ag delivery is the most efficient method of inducing local mucosal Ab
responses, a growing body of evidence supports the existence of an additional pathway
capable of stimulating mucosal Ab synthesis and/or protection from mucosal challenge
following nonmucosal Ag delivery (reviewed in Refs. 12 and 13). Peripheral, or nonmucosal
delivery of viral (14–21) and bacterial (22, 23) agents, as well as immunomodulatory factors
(24, 25) significantly augment mucosal Ab and/or T cell responses. Likewise, several
specialized nonmucosal delivery approaches have been developed which promote mucosal
immune induction such as parenteral targeting of mucosal lymphoid tissues using anti-
MAdCAM-1 Abs (26), Ag delivery through the skin in the presence of known mucosal
adjuvants (transcutaneous immunization) (27–29), and direct Ag inoculation into a
peripheral lymph node (targeted lymph node immunization) (30, 31).
Our laboratory recently demonstrated that nonmucosal delivery of modified virus particles
derived from the alphavirus, Venezuelan equine encephalitis virus (VEE), stimulates IgG
and IgA Ab production at multiple mucosal surfaces to both expressed and codelivered Ags
(18–20). The particles used in these studies, termed VEE replicon particles (VRP), express
only the viral nonstructural or replicase components responsible for replication of the
genomic RNA and can be engineered to express high levels of a heterologous protein (32).
VRP efficiently infect DCs following footpad inoculation in mice and replicate the modified
viral genome to high levels in the draining lymph node (DLN) (33). However, VRP fail to
propagate beyond the first infected cell, since progeny virions are not produced following
infection (34). In this study, we have used nonmucosal delivery of VRP as a model system
to dissect the individual components of a peripheral mucosal immune induction pathway.
VRP were used as an adjuvant in two separate test Ag systems: OVA and inactivated
influenza virus. In this report, we demonstrate that several markers of mucosal lymphoid
tissues are present in the lymph node draining the VRP inoculation site, such as mucosal
5Abbreviations used in this paper: MAdCAM-1, mucosal addressin cell adhesion molecule 1; DC, dendritic cell; DLN, draining
lymph node; HA, hemagglutinin; HEV, high endothelial venule; I-Flu, inactivated influenza virus; MLN, mesenteric lymph node;
VEE, Venezuelan equine encephalitis virus; VRP, VEE replicon particles; PP, Peyer's patch; PNAd, peripheral lymph node addressin;
IP, immunoprecipitation; IU, infectious unit.
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IgA Abs, mucosal cytokines (IL-6, TNF-α), and a mucosal homing profile. These
observations are consistent with a model in which, following nonmucosal VRP delivery, the
DLN is converted into the functional equivalent of a mucosal inductive site and serves as a
component of an alternative pathway for mucosal immune induction. These studies provide
a framework for the identification of the critical components of an alternative pathway for




The construction and packaging of VRP was performed as previously described (32, 35).
Briefly, confluent monolayers of BHK-21 cells were co-electroporated with three in vitro-
transcribed RNAs, the replicon RNA, and two defective helper RNAs encoding the viral
structural genes. Only the replicon RNA is packaged into VRP, because the helper RNAs
lack the viral packaging signal. In this study, three different replicon constructs were used:
1) replicons expressing GFP (GFP-VRP), 2) replicons expressing the hemagglutinin (HA)
gene from influenza virus (HA-VRP), and 3) replicons which lack a functional transgene
downstream of the 26S promoter (null VRP) (18). HA-VRP and null VRP were quantitated
by immunocytochemistry of infected BHK cells with antisera against HA (32) and null VRP
(18), respectively. GFP-VRP were quantitated by immunofluorescence of infected BHK
cells. All replicon particles used in this study were packaged in the wild-type (V3000)
envelope.
Animals and immunizations
Seven- to 10-wk-old female BALB/c mice were immunized with Ag and/or VRP in a 0.01-
ml volume in the rear footpad(s) as previously described (18) according to protocols
approved by the Institutional Animal Care and Use Committee. Briefly, animals were
immunized at weeks 0 and 4 with Ag alone or Ag coinoculated with either VRP or CpG
DNA as an adjuvant. Chicken egg albumin (OVA) was purchased from Sigma-Aldrich;
inactivated influenza virus (I-Flu) was purchased from Charles River Laboratories and was
dialyzed against PBS in a Slidalyzer cassette (Pierce) according to the manufacturer's
guidelines before use. CpG DNA (oligodeoxynucleotide 1826) was purchased from
InvivoGen. Diluent consisted of low endotoxin, filter-sterilized PBS, except for the
lymphoid organ culture experiments (see below), in which 110 mM Ca2+, 50 mM Mg2+, and
0.1% (v/v) donor calf serum were included.
Lymphoid organ cultures
Lymphoid cultures were prepared as previously described (18, 19). Briefly, spleen, nasal
tissue, and draining popliteal lymph nodes were harvested from immunized animals and
placed in Eppendorf tubes containing 1 ml of wash buffer (HBSS containing 100 U/ml
penicillin, 100 μg/ml streptomycin, 110 mM Ca2+, 50 mM Mg2+, and 15 mM HEPES) and
washed three times by aspiration and resuspension. Spleen and nasal tissue were placed in
individual wells of a 48-well tissue culture plate in 0.3 ml of medium (RPMI 1640 medium
(Life Technologies) containing 15 mM HEPES, 10% FBS, 100 U/ml penicillin, 100 μg/ml
streptomycin, 50 μg/ml gentamicin, 2 mM L-glutamine (Life Technologies), and 0.25 μg/ml
amphotericin B), and DLNs were placed in individual wells in a 96-well tissue culture plate
in 0.1 ml of medium. Plates were incubated at 37°C for 7 days to allow Ab secretion from
tissue-resident B cells into the supernatant. Following incubation, supernatants were
collected, clarified by centrifugation at 4°C, and analyzed for the presence of Ag-specific
Abs by ELISA and/or large molecular mass IgA Abs by nonreducing Western blot. A
limited set of tissue samples from an additional time point (day 21 after boost) was
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previously published in Thompson et al. (18) (Fig. 1) as evidence of VRP-induced mucosal
immune induction.
Preparation of DLN extracts
Draining popliteal lymph nodes were dissected from immunized animals, and each lymph
node was placed in a 1.5- ml tube (Kontes) with 0.1 ml of PBS containing protease
inhibitors (complete mini protease inhibitor mixture tablet (Roche)). DLNs were physically
homogenized with a plastic pestle (Kontes) with the aid of a hand-held motor and were
frozen at −20°C. Following thaw, debris were pelleted by centrifugation at 4°C, and
supernatants were analyzed for IgA Abs by ELISA or for cytokine production by Beadlyte
multiplex LUMINEX custom analysis performed by Millipore/Upstate Biotechnology (see
below). Extracts were compared from individual lymph nodes across the various
immunization groups. As a control, lymph node extracts were prepared from individual
Peyer's patches (PPs) exactly as described for the popliteal lymph nodes (homogenized in
0.1 ml of PBS).
Sera, fecal extracts, and vaginal washes
All sample collection was performed as previously described (18). Blood was harvested
from either the tail vein, following cardiac puncture, or from the submandibular plexus from
individual animals, and sera were collected following centrifugation in microtainer serum
separator tubes (BD Biosciences). For fecal extracts, fresh fecal pellets (5–8, ≈100–150 mg)
were isolated from individual animals and placed in a 1.5-ml Eppendorf tube containing 1
ml of fecal extract buffer (PBS containing 10% (v/v) normal goat serum and 0.1% (v/v)
Kathon CG/ICP (Supeleco)). Samples were vortexed for at least 10 min until all pellets were
disrupted into a homogenous mixture. Samples were clarified by centrifugation at 4°C, and
supernatants were transferred to fresh tubes and stored at −20°C before analysis by ELISA
(see below). Vaginal washes were performed by lavage of the exterior vaginal opening with
0.07 ml of PBS 8–10 times. Lavage samples were stored at −20°C and clarified at 4°C
before ELISA analysis (see below).
Flow cytometric analysis
DLNs were harvested from immunized animals, and the overall mass of the lymph nodes
was determined by weighing individual lymph nodes on an analytical balance. Each lymph
node was next disrupted with a razor blade and a hemostat, and single-cell suspensions were
created by agitating each lymph node in complete RPMI medium (RPMI 1640 medium
containing 10% (v/v) FBS, 2 mM L-glutamine, 50 μg/ml gentamicin, 100 U/ml penicillin,
100 μg/ml streptomycin, and 15 mM HEPES) containing 2.5 mg/ml collagenase A (Roche
Applied Science) and 17 μg/ml DNase I (Roche Applied Science) for 30 min at 37°C.
Single-cell suspensions were then stained with Abs directed against CD3, CD19, CD45
(B220), CD11c, CD11b (all purchased from eBioscience) as well as α4β7 integrin
(LPAM-1; clone DATK32) purchased from BD Pharmingen and examined on a BD
Biosciences FACSCalibur flow cytometer. Stained cells were analyzed using CellQuest
software (BD Biosciences).
ELISA
ELISAs for influenza- and OVA-specific Abs were performed on serum, fecal extracts,
vaginal washes, and lymphoid culture supernatants as previously described (18). Briefly, Ag
solutions (either 250 ng/ml influenza virus in carbonate buffer or 1 mg/ml OVA in PBS)
were incubated in 96-well plates overnight at 4°C to allow Ags to bind to the plate. Excess
Ag was removed, and blocking solution (PBS containing 5% milk for flu or 1×Sigmablock
(Sigma-Aldrich) for OVA) was added for 2 h for flu or overnight for OVA at room
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temperature. Following removal of blocking solution, plates were incubated at room
temperature for 2 h (flu) or overnight (OVA) with serial dilutions of individual samples
diluted in the appropriate blocking buffer. Plates were washed with a multichannel plate
washer (Nunc) and incubated for 1 h with HRP-conjugated secondary goat anti-mouse γ- or
α-chain-specific Abs (Southern Biotechnology Associates or Sigma). Finally, plates were
again washed, o-phenylenediamine dihydrochloride substrate was added for 30 min, and the
reaction was stopped with the addition of 0.1 M NaF. Ab end point titers are reported as the
reciprocal of the highest dilution that resulted in an OD450 ≥ 0.2. In lymphoid culture
supernatants, end point titers for flu-specific IgA are reported as the reciprocal of the highest
dilution that results in an OD450 reading at least 2 SDs greater than values obtained from
mock-vaccinated animals (Fig. 1). Data are presented as the geometric mean ± SEM.
Analysis of polymeric IgA
Lymph node (popliteal and PP) extracts were assayed for the presence of polymeric IgA Abs
by nonreducing Western blot analysis. Proteins were separated in Laemmli buffer in the
absence of reducing agent (no 2-ME) by 6% SDS-PAGE and transferred to polyvinylidene
difluoride membranes (Bio-Rad) in transfer buffer (48 mM Tris, 39 mM glycine, and 10%
methanol) at 12 V for 1 h. Membranes were subsequently blocked in PBS with 5% dry milk/
0.1% Tween 20 (Sigma-Aldrich) at room temperature overnight. Blocked membranes were
next washed in PBS with 1% dry milk/ 0.1% Tween 20 and incubated with a goat anti-IgA
Ab (Sigma-Aldrich and/or Southern Biotechnology Associates) at room temperature for 2 h.
Membranes were again washed and then incubated with a rabbit anti-goat HRP-conjugated
secondary Ab (Sigma-Aldrich) at room temperature for 1 h. Membranes were washed again
and HRP-conjugated Abs were detected via chemiluminescence with ECL detection
reagents (Amersham Pharmacia). For analysis of influenza-specific, polymeric IgA,
lymphoid culture supernatants were mixed with either influenza virus or an irrelevant virus
(Girdwood virus) for 2 h at 4°C, and virus-Ab complexes were cen-trifuged at 60,000 × g
for 30 min through a sucrose cushion. Pelleted virus-Ab complexes were resuspended in
nonreducing sample buffer and analyzed by IgA Western blotting as described above.
Detection of J chain
The presence of J chain was evaluated in a Western blot assay on DLN PBS extracts and
vaginal wash samples before and after immunoprecipitation with anti-IgA-coupled agarose
beads (Open Biosystems). Pre- and post-IgA precipitates derived from DLN extracts were
separated in Laemmli buffer by 15% SDS-PAGE and probed with anti-IgA-HRP (Southern
Biotechnology Associates), or anti-IgM-HRP (Southern Biotechnology Associates) as
described above, or with a biotinylated anti-mouse J chain mAb (36) (provided by T.
Leanderson, Lund University, Lund, Sweden), followed by incubation with streptavidin-
HRP and detection via ECL as described above. The mouse J chain protein is detected as an
∼25-kDa band in SDS-PAGE with the mAb used here (T. Leanderson, personal
communication) (36).
Statistical analysis
Ab titers and cytokine values were evaluated for statistically significant differences by either
the ANOVA or Mann-Whitney U test (GraphPad INSTAT). A p ≤0.05 was considered
significant.
Immunofluoresent staining of DLNs
To examine the addressin profile present in the DLN of immunized animals, DLNs were
harvested, snap frozen in liquid nitrogen, and sectioned. Frozen sections were stained with
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Abs against PNAd and MAdCAM-1 as previously described (37, 38) and analyzed by
confocal microscopy (Zeiss LSM510).
Cytokine/chemokine analysis
PBS homogenates of lymph nodes (see above) were analyzed for the presence of IL-1β,
TNF-α, IL-5, IL-6, IFN-γ, RANTES, GM-CSF, MIP-1β, TGF-β1, TGF-β2, and TGF-β3 on
a Luminex machine. Samples were analyzed by the Upstate Biotechnology/Millipore
Custom Multiplex cytokine analysis service. DLN samples were diluted 1/10 in PBS plus
protease inhibitors (see above) and were analyzed by Upstate Biotechnology. At least four
individual lymph nodes for each inoculum and time point were analyzed. For statistical
purposes, any analyte with a value below the assay limit of detection was assigned a value of
the limit of detection −1 pg/ml.
Results
The DLN is an early site of IgA production following VRP infection
To further characterize mucosal immune induction in the VRP system, the kinetics and
anatomical localization of IgA production following VRP delivery were determined. Groups
of female BALB/c mice were immunized in a rear footpad at weeks 0 and 4 with either
diluent, HA-VRP (1 × 105 infectious units (IU)), or formalin-inactivated I-Flu (10 μg),
which serves as a non-VRP-vectored Ag control. To evaluate the ability of VRP to induce
mucosal immunity to a codelivered Ag, an additional group of animals received I-Flu (10
μg) mixed with GFP-VRP (1 × 105 IU) as an adjuvant. Memory IgA responses were
evaluated following secondary inoculation, as our preliminary studies failed to detect IgA
responses after a primary immunization (data not shown). Groups of three animals were
sacrificed on days 3, 7, 14, and 28 after boost, and lymphoid organ cultures (18, 19) were
generated from the spleen (a characteristic systemic lymphoid tissue), the nasal epithelium
(a characteristic mucosal surface), and the draining popliteal lymph node (a candidate
component of an alternative mucosal immune induction pathway). Organ culture
supernatants were evaluated for the presence of influenza (flu)-specific IgG and IgA Abs by
ELISA. In general, the kinetics of flu-specific IgG and IgA Ab synthesis was similar in a
given tissue (Fig. 1). The dose of I-Flu used in this study (10 μg) was chosen because
preliminary studies showed that it induced an Ag-specific systemic IgG response similar to
that of HA-VRP, allowing assessment of the role of VRP in IgA production under
conditions of equivalent overall immune stimulation. Following delivery of I-Flu alone, flu-
specific IgG (Fig. 1A) and IgA (Fig. 1B) Abs were detectable in spleen organ culture
supernatants; however, flu-specific IgA Abs were significantly increased following either
delivery of HA-VRP or when GFP-VRP were coadministered with I-Flu. Likewise,
significantly increased flu-specific IgG (Fig. 1C) and IgA (Fig. 1D) Abs were detected in the
nasal epithelium of animals immunized with VRP-containing inocula. Flu-specific IgG (Fig.
1 E) and IgA (Fig. 1F) Abs also were detected in the supernatants from the DLNs following
delivery of Ag alone. These values were again significantly increased in animals immunized
with VRP as expression vectors or as adjuvants. Taken together, these results further
validate the utility of VRP expression vectors and VRP adjuvants.
This study was designed also to determine the anatomical location in which IgA Abs were
first produced in VRP-immunized animals. Flu-specific IgA Ab responses peaked in the
DLNs at day 3 after boost (Fig. 1F), a time at which such Abs were essentially undetectable
at the mucosal surface (Fig. 1D). In general, the responses induced by HA-VRP and I-Flu
plus VRP were not statistically different from one another at most time points. The
exceptions to this statement are that I-Flu plus VRP induced statistically stronger responses
compared with HA-VRP at: 1) day 3 DLN IgG (p < 0.01), 2) day 14 DLN IgG (p < 0.001),
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and 3) day 3 DLN IgA (p < 0.01). These results suggest that VRP-induced IgA production
occurs in the DLN before production at the mucosal surface and provide a foundation for the
further study of VRP-stimulated IgA synthesis in the DLN in the context of mucosal
immune induction.
The data presented in Fig. 1 suggested that IgA Abs were produced in the DLN following
VRP delivery and that such production was dependent upon signals provided by the VRP
and/or VRP infection, since equivalent levels of Ag-specific IgA Abs were not produced in
the DLN following delivery of Ag alone. This study was extended to determine whether IgA
production was occurring in vivo and was not an artifact of ex vivo incubation. Therefore,
groups of female BALB/c mice were immunized in a rear footpad at weeks 0 and 4 with I-
Flu alone (1 μg), or I-Flu (1 μg) code-livered with null VRP (1 × 105 IU), and DLNs were
harvested at days 1, 3, 7, and 14 after boost and homogenized in 0.1 ml of PBS.
Supernatants were evaluated for the presence of flu-specific IgA Abs by ELISA. Fecal
extracts also were prepared from immunized animals as a measure of mucosal immune
induction (18, 20). Ag-specific IgA Abs were detectable in DLN homogenates and the levels
peaked at day 3 after boost, similar to the kinetics of IgA production in the DLN in the
lymphoid culture system (Fig. 2A). Conversely, Ag-specific IgA Abs peaked in fecal
extracts at day 7 after boost, a time after peak production in the DLN (Fig. 2B). I-Flu alone
did not induce significant IgA production in either tissue.
We next sought to evaluate IgA production in the mucosa-draining lymphoid tissues in the
VRP system. As a first step, a single PP from each of six individual animals was harvested
and homogenized as described for DLNs. PP homogenates were evaluated for the presence
of flu-specific IgA Abs by ELISA; however, the mean values produced in PP homogenates
at all four time points tested were below the limits of detection of the ELISA and were not
statistically distinct from the assay background (Fig. 2C). Taken together, these results
suggest that, following nonmucosal VRP infection, Ag-specific IgA Abs are produced in
vivo in the DLN before production at mucosal surfaces.
VRP stimulate high molecular mass IgA Ab production in the DLN
Although delivery of VRP-containing inocula clearly increased the levels of Ag-specific IgA
Abs produced in the DLNs, Ag-specific IgA Abs also were produced at detectable levels
following delivery of I-Flu alone. Based on the idea that mucosal IgA Abs are polymeric,
the molecular mass of the IgA species produced in the DLN was determined following
delivery of both VRP-containing and non-VRP-containing inocula. Supernatants from day 3
DLN cultures were analyzed by SDS-PAGE under nonreducing conditions for the presence
of IgA Abs. To compare the ratio of monomeric to polymeric IgA on a per lymph node
basis, an equal amount of DLN supernatants were evaluated in the Western blot assay. The
IgA Abs in the DLN following delivery of I-Flu alone were predominantly monomeric, with
an apparent molecular mass of ∼160 kDa (Fig. 3A). Interestingly, the delivery of either HA-
VRP or I-Flu plus a VRP adjuvant resulted in the production of monomeric forms of DLN
IgA as well as large molecular (>250 kDa) forms not present at significant levels following
delivery of Ag alone (Fig. 3A). IgA Abs were not detected in the contralateral popliteal
lymph node under these conditions.
To determine whether VRP-induced high-molecular mass IgA Abs were specific for the
influenza Ag, day 3 DLN supernatants were incubated with influenza virus or an irrelevant
virus (Girdwood virus) and were pelleted through a sucrose cushion by ultracentrifugation.
This procedure utilized cosedimentation of influenza virions as a means to affinity purify
virus-specific Abs from non-flu-specific Abs before Western blot analysis. The flu-specific
IgA Abs present in the DLN following delivery of I-Flu were predominantly monomeric.
Immunization with either HA-VRP or I-Flu plus GFP-VRP resulted in the production of
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both a monomeric species of flu-specific IgA, as well as two high-molecular mass forms not
present at appreciable levels following delivery of I-Flu alone (Fig. 3B). Taken together,
these results suggest that VRP infection provides a signal which promotes the production of
high-molecular mass IgA molecules in the DLN.
To evaluate the presence of polymeric IgA Abs in the DLN in vivo, groups of female
BALB/c mice were immunized at weeks 0 and 4 with either OVA alone (10 μg) or OVA
mixed with null VRP (1 × 105 IU). An additional group of animals was immunized with
OVA (10 μg) mixed with CpG DNA (1 μg) as a control adjuvant known to induce mucosal
immunity following nonmucosal delivery, albeit at lower levels compared with VRP (18).
At day 3 after boost, DLN homogenates were prepared and evaluated for the presence of
IgA Abs by nonreducing Western blot analysis as described above. As shown in Fig. 3C,
IgA Abs were not detectable in the DLN following delivery of OVA alone or following
codelivery of OVA with CpG DNA. In contrast, both monomeric and dimeric forms of IgA
were produced in the VRP DLNs, suggesting that high-molecular mass IgA Abs are
produced in the DLN in vivo.
Role of exogenous Ag in DLN polymeric IgA production
An additional experiment was performed to determine whether the production of polymeric
IgA Abs in the DLN was dependent upon exogenous Ag stimulation, or whether Ags
naturally present in the DLN have the capacity to promote IgA production during a
concomitant VRP infection. Groups of female BALB/c mice were immunized at weeks 0
and 4 with either I-Flu alone (1 μg), I-Flu (1 μg) mixed with null VRP (1 × 105 IU), or null
VRP alone (1 × 105 IU), and DLN homogenates in PBS were prepared at day 3 after boost
and analyzed for the presence of IgA by Western blot under nonreducing conditions. As
shown in Fig. 4A, VRP induced the production of both monomeric and polymeric forms of
IgA following codelivery with Ag. In contrast, IgA Abs were not detected following
delivery of either Ag alone or null VRP alone when comparing equal proportions of DLN
lysate, suggesting that antigenic stimulation, in addition to VRP infection, is required to
promote polymeric IgA synthesis in the DLN.
At mucosal sites, the formation of dimeric and polymeric IgA is dependent upon
incorporation of the J chain during IgA secretion (10). Therefore, to further characterize the
mucosal nature of DLN IgA Abs, we next evaluated day 3 DLN PBS homogenates
(described above) for the presence of J chain in a Western blot assay. Our analysis of DLN
homogenates revealed the presence of IgM Abs in addition to IgA Abs (data not shown).
Therefore, DLN homogenates were subjected to immunoprecipitation (IP) using anti-IgA-
agarose beads to analyze J chain content specifically in the IgA fractions in the DLN, as
opposed to J chain present in pentameric IgM complexes. IgM Abs were no longer detected
following IgA IP (data not shown). As a control, J chain content was also analyzed in
vaginal wash fluids from immunized mice by SDS-PAGE under reducing conditions. An
∼24-kDa band, corresponding to the J chain (36) (T. Leanderson, personal communication),
was present in vaginal washes from animals immunized with I-Flu alone and I-Flu plus VRP
(Fig. 4B). Comparing equal proportions of the DLN lysates, a J chain band of weak intensity
was present in post-IgA IP lysates prepared from animals immunized with I-Flu alone. In
contrast, the J chain was readily detectable in both pre- and post-IgA IP DLN lysates
following immunization with I-Flu plus VRP (Fig. 4B), indicating that the J chain is
incorporated into VRP-induced polymeric DLN IgA.
Although the data presented in Figs. 3 and 4A suggested that delivery of both VRP and Ag
were required for DLN IgA production, we considered the possibility that IgA Abs may, in
fact, be produced in the DLN following delivery of Ag alone at levels not detectable when
comparing equal proportions of DLN lysates. Therefore, day 3 DLN lysates were subjected
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to IgA Western blot analysis as described above; however, increasing amounts of I-Flu DLN
lysates (1×, 4×, 8×, and 12×) were electrophoresed and compared with a 1× amount of I-Flu
plus VRP lysate (Fig. 4C). As additional controls, monomeric and polymeric IgA Abs were
also analyzed in serum and vaginal wash fluids. Consistent with previous reports (39, 40),
both monomeric and polymeric species of IgA were present in the serum of immunized
animals, regardless of the inoculum (Fig. 4C). Additionally, IgA Abs present in vaginal
lavage fluids were almost exclusively polymeric (Fig. 4C). Although inclusion of VRP in
the inoculum clearly increased IgA production in the DLN, analysis of increasing amounts
of DLN lysate from I-Flu-inoculated animals revealed both monomeric and polymeric IgA
species present in the DLNs when 8- and 12-fold more lysate was analyzed compared with
I-Flu plus VRP (Fig. 4C). Furthermore, polymeric IgA Abs were present in day 3 DLN
lysates from unmanipulated animals as well as PBS-immunized mice, albeit at lower levels
(data not shown). Taken together, these results demonstrate that peripheral delivery of VRP
significantly increased monomeric and polymeric IgA production in the draining peripheral
lymph node.
Characterization of DLN cells following VRP delivery
The observation that the DLN appeared to serve as the earliest site of IgA production, and
high-molecular mass Ag-specific IgA following VRP delivery, led us to further characterize
the general characteristics of the DLN under these conditions. The overall mass of the DLN,
a general marker of inflammation, as well as the general cellularity of the DLN were
determined. Groups of animals were immunized with either I-Flu alone (1 μg), I-Flu (1 μg)
mixed with null VRP (1 × 105 IU), or null VRP alone (1 × 105 IU), and DLNs were
harvested at days 0, 1, and 3 after boost. DLNs were carefully weighed on an analytical
balance to determine overall mass, and single-cell suspensions were created by collagenase
digestion. Total cell counts were performed by trypan blue exclusion, and cells were
analyzed by flow cytometry for the presence of B cells, T cells, and dendritic cells (DCs)
following staining with Abs directed against the appropriate cell surface markers (CD19,
CD3, and CDllc, respectively). As shown in Fig. 5A, VRP delivery in the presence or
absence of codelivered Ag resulted in a 2- to 4-fold increase in the overall mass of the DLN,
depending upon the time point examined. Moreover, the total cellularity of the VRP DLN
was increased by 4- to 6-fold (Fig. 5B). VRP induced a proportional 3- to 10-fold increase in
B cells, T cells, and CD11b− DCs in the DLN at days 1 and 3 after boost (Fig. 5, C–E).
Also, VRP infection led to an ∼20-to 40-fold increase in the number of CD11b+ DCs in the
DLN at days 1 and 3 after boost, both in the presence and absence of exogenous Ag (Fig.
5F). These results suggest that VRP delivery results in significantly increased cellularity in
the inflamed DLN independent of exogenous Ag delivery, with a preferential recruitment of
a CD11b+ DCs.
Presence of α4β7 integrin-positive B cells in the VRP DLN
Because VRP infection resulted in recruitment of B cells to the DLN, we next sought to
evaluate such cells for characteristics of mucosal B cells, such as expression of the mucosal
homing receptor. Groups of female BALB/c mice were immunized in a rear footpad at
weeks 0 and 4 with either OVA alone (10 μg) or OVA (10 μg) coinoculated with null VRP
(1 × 105 IU), and DLNs were harvested at days 1 and 3 after boost. Single-cell suspensions
were generated by collagenase digestion, and DLN B cells were analyzed for expression of
CD19, B220, and the α4β7 integrin by flow cytometry. Additionally, single-cell suspensions
prepared from the mesenteric lymph node (MLN) were also analyzed as a representative
mucosal lymphoid tissue. As shown in Fig. 6A, the α4β7 integrin was expressed to similar
levels on B cells isolated from the MLN at both days 1 and 3, regardless of the immunizing
inoculum. Analysis of DLN B cells revealed two populations of B cells according to B220
expression levels; a B220highCD19high population and a B220lowCD19high population (Fig.
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6). Expression levels of the α4β7 integrin were analyzed on both populations at days 1 and 3
after boost. As shown in Fig. 6B, a small B220low population of B cells was present in the
DLN of animals inoculated with OVA alone at day 1 after boost. Increased α4β7 integrin
expression was observed in a subset of these B220low B cells (Fig. 6B, see inset). Delivery
of OVA in the presence of VRP resulted in a significantly increased population of B220low
B cells with up-regulated α4β7 integrin expression at day 1 after boost (Fig. 6B). The α4β7
integrin levels were comparable to those of MLN B cells (Fig. 6A). Interestingly, although a
B220low population was still present in the DLN following delivery of OVA in the presence
or absence of VRP at day 3 after boost, this population of cells no longer expressed
increased levels of the α4β7 integrin (Fig. 6B). Increased α4β7 integrin expression was
detected on a subset of B220high B cells at day 3 following delivery of OVA alone (Fig. 6B).
To determine the proportion of B220low DLN B cells with up-regulated α4β7 integrin
expression, as well as to evaluate the role of exogenous Ag delivery in mucosal homing
receptor expression following delivery of a viral Ag, an additional experiment was
performed. Groups of mice were immunized at weeks 0 and 4 with either I-Flu alone (1 μg),
I-Flu (1 μg) plus null VRP (1 × 105 IU), or null VRP alone (1 × 105 IU), and α4β7 integrin
expression was evaluated on DLN B cells at day 0 (before boost), day 1, and day 3 after
boost. As shown in Fig. 6C, α4β7 integrin expression was induced in the B220low population
at day 1 after boost and was again undetectable at day 3. Moreover, VRP induced increased
α4β7 integrin expression either when coinoculated with a viral Ag or when delivered in the
absence of any exogenous Ag, suggesting that the signals which catalyze increased mucosal
homing receptor expression are active during VRP infection. Taken together, these data
suggest that peripheral inoculation of VRP results in a mucosal homing profile of DLN B
cells that is similar to the homing profile of B cells isolated from mucosal lymphoid tissues
(the MLN).
VRP induce MAdCAM-1 expression on the HEVs of the DLN
Although PNAd expression can be detected on the HEVs of both systemic and mucosal
lymphoid tissues (7, 8), MAdCAM-1 expression is distinctive characteristic of mucosal
lymphoid tissues (41). Therefore, next we evaluated MAdCAM-1 expression levels in the
VRP DLN. Female BALB/c mice were immunized in both rear footpads with either I-Flu
alone (1 μg), null VRP alone (1 × 105 IU), I-Flu (1 μg) plus null VRP (1 × 105 IU), or I-Flu
(1 μg) plus CpG DNA (1 μg) at weeks 0 and 4. DLNs were harvested from immunized
animals at days 1, 2, and 3 after boost, snap frozen in liquid nitrogen, sectioned, and
analyzed for expression of MAdCAM-1 and PNAd by confocal microscopy. Sections
derived from MLN served as a mucosal lymphoid tissue-positive control. As expected,
expression of both PNAd (green) and MAdCAM-1 (red) were readily detectable on the HEV
of the MLN, including double-positive cells (yellow, Fig. 7A). PNAd staining was abundant
in the DLN following delivery of I-Flu alone at all time points examined, consistent with a
systemic lymphoid tissue phenotype (Fig. 7B). Interestingly, MAdCAM-1 expression was
detected in the DLN following delivery of I-Flu in the presence of VRP beginning at day 2
after boost, with increased expression at day 3 after boost. Expression of MAdCAM-1 was
also noted on the DLN following null VRP injections, although expression was not as
abundant (Fig. 7C). Analysis of MAdCAM-1 staining suggested that endothelial cells lining
the HEV up-regulated MAdCAM-1, similar to expression in mucosal lymphoid tissues, such
as the MLN (Fig. 7, C and D). Both “1st type” staining, in which a single cell inside the
vessel is detected (these cells could be endothelial cells), as well as “2nd type,” in which
MAdCAM-1 is clearly expressed by the endothelial cells were apparent in the VRP DLN
(Fig. 7D). Additionally, positive staining was also detected in the DLN following delivery of
I-Flu plus CpG DNA at day 3, however, to a lesser extent (Fig. 7D). As MAdCAM-1
expression was present following delivery of null VRP alone as well as Ag plus null VRP,
Thompson et al. Page 10













these data suggest this “profile change” is Ag independent. These results suggest that
stimulation of an alternative mucosal inductive pathway by VRP results in an HEV profile
in the DLN which, distinct from traditional systemic lymphoid tissues, exhibits
characteristics of mucosal lymph nodes.
VRP drive mucosal cytokine/chemokine production in the DLN
To further characterize the mucosal characteristics of the VRP-DLN, the expression levels
of representative Th1/Th2 cytokines, inflammatory cytokines, and mucosally relevant
chemokines were evaluated in the DLN in a Luminex assay. Groups of female BALB/c mice
were immunized in the rear footpads at weeks 0 and 4 with either OVA alone (10 μg), OVA
(10 μg) coinoculated with null VRP (1 × 105 IU), or OVA (10 μg) plus CpG DNA (1 μg)
and DLNs were harvested at 6, 12, and 24 h after boost. DLN homogenates in PBS were
prepared as described above. Homogenates were analyzed for expression of IL-1β, IL-5,
IL-6, TNF-α, IFN-γ, MIP-1β, RANTES, TGF-β1, 2, and 3 in a LUMINEX assay by
Upstate Biotechnology/Millipore (Fig. 8). Although generally VRP-induced cytokine/
chemokine production peaked at 6 h after boost and decreased over the time course, subtle
differences existed between the kinetics of expression of the individual proteins. The
inclusion of VRP in the inoculum significantly increased expression of IL-1β (11-fold), IL-5
(3.5-fold), IL-6 (16.5-fold), TNF-α (7-fold), IFN-γ (5-fold), MIP-1β (27-fold), and
RANTES (6.5-fold) at the 6- and/or 12-h time points compared with delivery of Ag alone.
Additionally, preliminary experiments suggest that VRP likewise up-regulate IL-4 in the
DLN (data not shown). Although significant levels of all three subtypes of TGF-β were
present in the DLN at 6 h, VRP infection did not induce a statistically significant increase in
these proteins and responses were quite variable (data not shown). As a control, we also
evaluated the levels of the same eight cytokines in PP homogenates from the same animals;
however, protein levels in this tissue were below the limits of the LUMINEX assay (data not
shown). This analysis suggests that VRP significantly augment the production of several
mucosally relevant cytokines and chemokines in the DLN which may affect the
development of specific T cell subsets involved in the mucosal adjuvant effect.
Discussion
Mucosal Ag delivery in the presence of strong mucosal adjuvants, such as the bacterial
enterotoxins, results in Ag processing in the mucosal lymphoid structures, stimulates potent
mucosal IgA responses, and has revealed the components and immune inductive
requirements of the natural pathway of mucosal immune induction (1, 42, 43). However, it
has become increasingly clear that nonmucosal Ag delivery also can result in mucosal
immune induction under specific conditions (12–14, 16, 17, 19–25, 28, 30, 31, 44). The
molecular mechanisms which regulate peripherally induced mucosal immunity are poorly
understood at present. The examples are varied and suggest either a consistent unifying
mechanism is responsible for such induction under all circumstances or, conversely, that
numerous diverse signals have the capacity to drive mucosal immunity following
nonmucosal delivery.
It is possible that mucosal immune induction following nonmucosal delivery is merely a
result of stimulating components of the natural pathway, as has been proposed by McKenzie
et al. (26), following peripheral delivery of anti-MAdCAM-1 Abs. Conversely, mucosal
immune induction following nonmucosal delivery may be a result of stimulating an
alternative pathway for mucosal immune induction, a pathway with components distinct
from those of the natural pathway. Another, nonmutually exclusive, possibility is that
specific vaccine signals promote the generation of a “mucosal-like” site outside of the
mucosal compartment. We hypothesize that this is the mechanism by which VRP promote
mucosal immune induction following nonmucosal delivery. Several characteristics of
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mucosal lymphoid tissues are observed in the DLN of VRP-immunized mice, suggesting
that under these conditions, the DLN is “converted” to the functional equivalent of a
mucosal inductive site.
To test this “conversion” hypothesis in the VRP system, we first sought to determine the
anatomical location in which IgA Abs are produced following VRP delivery. Such analysis
revealed that Ag-specific IgA Abs were first detected in the popliteal lymph node draining
the site of VRP inoculation, before Ab production at mucosal surfaces. Moreover, further
characterization of DLN IgA Abs revealed the presence of J chain-containing, polymeric
forms in the DLN, which resemble IgA Abs found at mucosal sites. This finding is
consistent with the production of oligomeric IgA Abs in the peripheral DLN following
delivery of CFA (45), and is supportive of a model in which the DLN serves as the primary
inductive tissue for the activation of mucosal immune responses following footpad VRP
delivery.
Interestingly, the peripheral DLN has been implicated in three other models of mucosal
immune activation following nonmucosal delivery. First, Enioutina et al. (25) demonstrated
that the active form of vitamin D3 augments mucosal IgA responses in a peripheral delivery
model. As in the VRP system, IgA-producing cells, and a “mucosal-like” cytokine profile
were present in the DLN following vitamin D delivery; however, the presence of J chain-
positive, polymeric IgA was not evaluated in those studies (25, 46). Second, following i.m.
rotavirus delivery, cells isolated from the peripheral DLN induced gut IgA and IgG
responses following adoptive transfer into naive recipients (15). Third, in targeted lymph
node immunization, Ags are inoculated directly into the lymph node itself, promoting Ag
acquisition and processing by lymph node-resident cells. This inoculation regimen induces
IgA Ab synthesis in the local inoculated lymph node as well as in mucosal secretions, in the
absence of Ag processing in other peripheral lymphoid structures (30). Additionally,
expression of RANTES and MIP-1β, both of which were highly up-regulated in the DLN by
VRP, correlated with lymph node IgA production in the DLN in this model (47). Indeed,
Lehner et al. (47) proposed that the affected lymph node serves as an inductive site for the
generation of cells with protective properties at the local mucosal surface. These examples,
along with the data presented here, suggest a critical role for the DLN in peripherally
induced mucosal immune induction.
It is attractive to speculate that, as a consequence of B cell activation within the lymph node
draining VRP inoculation, such cells undergo IgA class switch, initiate pIgA production, and
migrate to the mucosal surface where they continue to secrete pIgA Abs some days later.
Characterization of the VRP DLN revealed the presence of both α4β7 integrin-positive B
cells and expression of MAdCAM-1 on the HEVs, potentially implicating mucosal homing
receptor interactions in VRP-induced mucosal immunity. Interestingly, however, α4β7
integrin-positive B cells were present in the DLN at day 1 after boost, a time in which
MAdCAM-1 expression was not detected. Instead, MAdCAM-1 expression kinetics
correlated with the kinetics of IgA Ab production in the DLN, suggesting that the
involvement of MAdCAM-1 may not be in the recruitment of IgA-producing cells to the
DLN but rather in the retention of such cells in the DLN. Further experimentation will be
required to define the precise role of the α4β7 integrin-MAdCAM-1 pathway in mucosal
immune induction following nonmucosal VRP infection.
Identification of the essential cell type(s) in the DLN which promote a mucosal environment
has yet to be performed; however, we considered the potential role of lymph node DCs in
the VRP experimental system. A large body of evidence supports the notion that mucosal
DCs are qualitatively distinct from systemic DCs in priming mucosally relevant B cell and T
cell responses (Refs. 48–51 and reviewed in Refs. 52 and 53). For example, Mora et al. (54)
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recently demonstrated increased α4β7 integrin expression and mucosal homing of CD8+ T
cells cocultured with mucosal, but not systemic DCs. Likewise, Sato et al. (55) demonstrated
that mucosal CDllb+ DCs promote IgA synthesis from cocultured B cells by producing large
amounts of IL-6, as mucosal DCs cultured in the presence of an anti-IL-6 Ab failed to
stimulate IgA production. It is interesting in this regard that VRP infection stimulated a
strong IL-6 response in the DLN.
Of note, the mucosal DCs responsible for driving IgA production in the experimental system
described by Sato et al. were CDllb+, the same population of DCs that were dramatically
increased in the DLN of VRP-immunized mice. Indeed, preliminary experiments suggest
that the CDllb+ DC population represents the major target of VRP infection in the DLN
(data not shown); however, whether these cells represent the cellular source of DLN IL-6 or
the DLN/mucosal IgA response remains to be determined. It is possible that VRP not only
rely upon the DLN for mucosal immune induction, but that VRP infection promotes a
“mucosal DC-like” phenotype in DLN CD11b+ DCs, potentially through IL-6 production.
Of note, Mora et al. (48) recently demonstrated the ability of mucosal DC-derived retinoic
acid to promote IgA secretion and increased α4β7 integrin expression in vitro (48). It will be
interesting to determine whether VRP-infected DCs possess the capacity to drive either
increased α4β7 integrin expression or IgA production in vitro, and specifically whether
soluble IL-6 and/or retinoic acid are implicated in the VRP system.
The data presented here implicate the DLN in mucosal immune induction in the VRP
system; however, elements of the natural mucosal induction pathway also may be involved.
It is possible that VRP-infected DCs migrate beyond the DLN to PPs and/or MLN following
footpad delivery and initiate mucosal immune induction following migration to known
mucosal inductive tissues as has been proposed following both transcutaneous immunization
(56) and Ag delivery in the presence of vitamin D3 (57). However, a series of experiments
have failed to experimentally support such an hypothesis. Analysis of PP, MLN, and nasal-
associated lymphoid tissue following peripheral delivery of GFP-VRP has failed to
reproducibly detect VRP-infected cells in these tissues (J. M. Thompson, E. M. Richmond,
and R. E. Johnston, unpublished observations). Additionally, Ag-specific Abs were not
detected in PP homogenates from VRP-immunized animals under conditions where Ag-
specific polymeric IgA was readily detectable in the DLN. Thus, it is unlikely that infection
of mucosal lymphoid tissues represents the predominant mechanism of immune induction in
the VRP system.
In summary, nonmucosal delivery of alphavirus replicon particles has been used as a model
system to dissect the organization of an alternative pathway for mucosal immune induction.
The draining peripheral lymph node appears to be the central component of this pathway, as
the VRP-infected DLN produced J chain-containing, polymeric forms of IgA, increased
mucosal cytokines, a population of B cells harboring a mucosal homing phenotype, and
mucosal-like HEVs. Identification of the essential viral and immunological factors which
regulate mucosal immune induction following nonmucosal VRP delivery may shed new
light on an alternative pathway for mucosal immune induction. Moreover, such insights may
allow robust stimulation of this alternative pathway, resulting in vaccines with protective
efficacy against mucosal pathogens and consequently reduced morbidity/mortality
associated with such infections.
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The DLN is an early site of IgA production following VRP infection. Groups of BALB/c
mice were immunized in the rear footpad with HA-VRP (1 × 105 IU), I-Flu alone (10 μg),
or I-Flu (10 μg) plus GFP-VRP (1 × 105 IU) as an adjuvant at weeks 0 and 4. At the
indicated time points, lymphoid organ cultures were established from the spleen (A and B),
nasal epithelium (C and D), and DLN (E and F) and evaluated for the presence of flu-
specific IgG (A, C, and E) and IgA Abs (B, D, and F) by ELISA. Values represent mean ±
SEM. *, p < 0.05; **, p < 0.01; and ***, p < 0.001 compared with I-Flu alone, as
determined by ANOVA.
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VRP induce IgA Ab production in the DLN in vivo. Groups of BALB/c mice were
immunized in the rear footpad with I-Flu alone (1 μg), or I-Flu (1 μg) plus null VRP (1 ×
105 IU) at weeks 0 and 4. At the indicated time points, flu-specific IgA Abs were evaluated
in DLN homogenates (A), fecal extracts (B), and PP homogenates (C) by ELISA. Values
represent mean ± SEM. *, p < 0.05; **, p < 0.02; and ***, p < 0.003 compared with I-Flu
alone, as determined by the Mann-Whitney U test.
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VRP induce the production of large molecular mass IgA Abs in the DLN. Groups of BALB/
c mice were immunized in the rear footpad with HA-VRP (1 × 105 IU), I-Flu alone (10 μg),
or I-Flu (10 μg) plus GFP-VRP (1 × 105 IU) at weeks 0 and 4. At day 3 after boost, DLN
and contralateral lymph node (CLN) culture supernatants were evaluated for IgA Abs by
nonreducing Western blot analysis (A). Day 3 DLN supernatants were then mixed with
influenza virus to form virus-Ab complexes and complexes were purified via
ultracentrifugation before nonreducing Western blot analysis for IgA (B). Groups of BALB/
c mice were immunized in the rear footpads with OVA alone (10 μg), OVA (10 μg) plus
null VRP (1 × 105 IU), or OVA (10 μg) plus CpG DNA (1 μg) at weeks 0 and 4 and DLNs
were harvested at day 3 and DLN PBS homogenates were evaluated for IgA Abs by
nonreducing Western blot analysis as in A (C). The gel lanes in A have been rearranged
from the original order for esthetic purposes; however, the data are all from the same gel
from a single experiment.
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Role of exogenous Ag in DLN polymeric IgA production. Groups of BALB/c mice were
immunized in the rear footpads at weeks 0 and 4 with I-Flu alone (1 μg), I-Flu (1 μg)
coinoculated with null VRP (1 × 105 IU), or null VRP alone (1 × 105 IU). At day 3 after
boost, DLNs were harvested and PBS extracts were prepared and equal proportions of
lysates were analyzed for the presence of IgA Abs by Western blot under nonreducing
conditions (A). DLN Abs were evaluated for the presence of the J chain by reducing
Western blot analysis. The mouse J chain protein is detected as an ∼25-kDa band in SDS-
PAGE with the mAb used here (T. Leanderson, personal communication) (36) (B). Vaginal
wash (VW) fluids and DLN PBS extracts were probed with an anti-mouse J chain mAb
before and following IgA IP (B). IgA Abs were also evaluated in serum and VW fluids by
nonreducing Western blot analysis (C). Additionally, levels of IgA Abs were evaluated in
increasing amounts of I-Flu DLN lysates (1×, 4×, 8×, 12×) compared with 1× of I-Flu plus
VRP lysates (C).
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Characterization of VRP DLN cells. Groups of BALB/c mice were immunized in the rear
footpads at weeks 0 and 4 with I-Flu alone (1 μg), I-Flu (1 μg) coinoculated with null VRP
(1 × 105 IU), or null VRP alone (1 × 105 IU). At days 0, 1, and 3 after boost, DLNs were
harvested and weighed on an analytical balance and single-cell suspensions were prepared
by collagenase digestion. The mass of each lymph node was determined (A) and total
number of cells was determined by trypan blue exclusion (B). The number of B cells (C), T
cells (D), CD11b− DCs (E), and CD11b+ DCs (F) was evaluated by flow cytometry. Values
are presented as geometric mean ± SEM. *, p < 0.05; **, p < 0.01; and ***, p < 0.001
compared with I-Flu alone, as determined by ANOVA.
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VRP induce the expression of the mucosal homing receptor on DLN B cells. Groups of
animals were immunized in the rear footpad at weeks 0 and 4 with OVA alone (10 μg) or
OVA (10 μg) coinoculated with null VRP (1 × 105 IU). At days 1 and 3 after boost, DLN
cells were stained with Abs directed against CD19, B220, and the α4β7 integrin and
analyzed by flow cytometry. As a positive control, α4β7 integrin expression was examined
on MLN cells (A). α4β7 integrin expression in both B220high and B220low DLN cells is
shown in B. The histograms in A and B are all on the same scale, except the expanded inset
in B. To confirm the up-regulation of α4β7 integrin expression specifically in the B220 low
population following delivery of a viral Ag, α4β7 integrin expression was analyzed on DLN
cells at days 0, 1, and 3 after boost following delivery of I-Flu alone (1 μg), I-Flu (1 μg)
plus null VRP (1 × 105 IU), or null VRP alone (1 × 105 IU) (C). Values are presented as
geometric mean ± SEM. *, p < 0.001 compared with I-Flu alone, as determined by ANOVA.
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VRP up-regulate MAdCAM-1 in the DLN. Groups of female BALB/c mice were
immunized with at weeks 0 and 4 with I-Flu alone (1 μg), I-Flu (1 μg) coinoculated with
null VRP (1 × 105 IU), or I-Flu (1 μg) coinoculated with CpG DNA (1 μg) and DLNs were
harvested and snap frozen in OCT in liquid nitrogen at days 1, 2, and 3 after boost. MLN
(A) and DLN sections were stained with Abs directed against MAdCAM-1 (red) and PNAd
(green) analyzed by confocal microscopy and visualized at ×10 (B) and ×40 (C).
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VRP up-regulate mucosal cytokine/chemokine production in the DLN. Groups of female
BALB/c mice were immunized with at weeks 0 and 4 with OVA alone (10 μg), OVA (10
μg) coinoculated with null VRP (1 × 105 IU), or OVA (10 μg) inoculated with CpG DNA (1
μg), and PBS homogenates were created from the DLNs at 6, 12, and 24 h after boost. DLN
homogenates were evaluated for the presence of IL-1β (A), IL-5 (B), IL-6 (C), TNF-α (D),
IFN-γ (E), MIP-1α (F), and RANTES (G) via LUMINEX. Values are presented as
geometric mean ± SEM. *, p < 0.03 compared with OVA alone, as determined by the Mann-
Whitney U test.
Thompson et al. Page 25
J Immunol. Author manuscript; available in PMC 2013 March 20.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
